Bing Zhang

6PUBLICATIONS
1CO-AUTHORS
Cheminformatics and quantitative structure-activity relationshipsBiomolecular modelling and designProteins and peptidesPharmaceutical delivery technologiesClinical pharmacology and therapeutics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 11, 2025
Design, Synthesis, and Biological Evaluation of Heterocycle-Fused Celastrol Derivatives as Potent Antiosteoporosis Agents by Blocking RANKL-Induced Activation of the NF-κB and MAPK Signaling Pathways.

Xuefeng Fu, Chengjun Wu, Wen Jiang

|Aug 06, 2025
Discovery of 1-Difluoromethyl-3-(3-cyanophenyl)-6-[4-(trifluoromethoxy)phenyl]imidazo[1,5-<i>a</i>]pyrazin-8-(7<i>H</i>)-one as a Potent P2Y<sub>1</sub> Antagonist for the Treatment of Ischemic Stroke and Myocardial Infarction.

Bing Zhang, Jinxin Li, Ruyu Wang

|May 15, 2025
Design, Synthesis, and Biological Evaluation of 4-(Difluoromethyl)-1<i>H</i>-imidazole-5-carboxylic Acids/4-(3-Cyanophenoxy)pyrimidine-5-carboxylic Acids as P2Y<sub>1</sub> Receptor Antagonists for Ischemic Stroke Treatment.

Bing Zhang, Jinxin Li, Qi Li

|Aug 06, 2024
Scaffold Hopping of Pristimerin Provides Derivatives Containing a Privileged Quinoxaline Substructure as Potent Autophagy Inducers in Breast Cancer Cells.

Xuefeng Fu, Yang Jiao, Yao Feng

|Mar 11, 2022
Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis.

Jiaxing Zhao, Bing Zhang, Qing Mao

|Dec 14, 2020
Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y<sub>1</sub> and P2Y<sub>12</sub> as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.

Yu Lei, Bing Zhang, Dan Liu

Pageof 1

Frequent Collaborators

5 joint publications

Shaojie Wang